Fig. 4

Baseline levels of anti-CMV IgG differ in older subjects randomized to B. longum + Gl-OS and placebo. Data are anti-CMV IgG (AU/ml) ± 2SEM for n = 45 young and n = 45 older subjects randomized to B. longum + Gl-OS or placebo. Data were analysed using Student’s independent t-tests for differences between young and older subjects. * Denotes significant difference between treatment groups within age cohort (p < 0.05)